title: Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.
abstract: NK cells are promising effectors for tumor adoptive immunotherapy, particularly when considering the targeting of MHC class I low or negative tumors. Yet, NK cells cannot respond to many tumors, which is particularly the case for nonhematopoietic tumors such as carcinomas or melanoma even when these cells lose MHC class I surface expression. Therefore, we targeted primary human NK cells by gene transfer of an activating chimeric receptor specific for HER-2, which is frequently overexpressed on carcinomas. We found that these targeted NK cells were specifically activated upon recognition of all evaluated HER-2 positive tumor cells, including autologous targets, as indicated by high levels of cytokine secretion as well as degranulation. The magnitude of this specific response correlated with the level of HER-2 expression on the tumor cells. Finally, these receptor transduced NK cells, but not their mock transduced counterpart, efficiently eradicated tumor cells in RAG2 knockout mice as visualized by in vivo imaging. Taken together, these results indicate that the expression of this activating receptor overrides inhibitory signals in primary human NK cells and directs them specifically toward HER-2 expressing tumor cells both in vitro and in vivo.
authors.affiliation: Max-Delbrück Center for Molecular Medicine, D-13092 Berlin, Germany.
authors.forename: Anna
authors.initials: A
authors.lastname: Kruschinski
authors.forename: Andreas
authors.initials: A
authors.lastname: Moosmann
authors.forename: Isabel
authors.initials: I
authors.lastname: Poschke
authors.forename: Håkan
authors.initials: H
authors.lastname: Norell
authors.forename: Markus
authors.initials: M
authors.lastname: Chmielewski
authors.forename: Barbara
authors.initials: B
authors.lastname: Seliger
authors.forename: Rolf
authors.initials: R
authors.lastname: Kiessling
authors.forename: Thomas
authors.initials: T
authors.lastname: Blankenstein
authors.forename: Hinrich
authors.initials: H
authors.lastname: Abken
authors.forename: Jehad
authors.initials: J
authors.lastname: Charo
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000276:immunology* / Q000628:therapy*; D004268:DNA-Binding Proteins / Q000235:genetics; D005818:Genetic Engineering / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology*; D008156:Luciferases; D051379:Mice; D018345:Mice, Knockout; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology* / Q000378:metabolism
chemical_list: D004268:DNA-Binding Proteins; D008156:Luciferases; D018719:Erb-b2 Receptor Tyrosine Kinases; C499308:Rag2 protein, mouse; C508053:ERBB2 protein, human